Search results
Showing 121 to 135 of 161 results for prostate cancer
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
This indicator covers the proportion of cancer cases detected at stage 1 or 2. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Evidence-based recommendations on laparoscopic cystectomy. This involves removing the bladder using small cuts in the abdomen (keyhole surgery).
View recommendations for IPG287Show all sections
Sections for IPG287
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
This guidance has been updated and replaced by NICE guideline CG175.
This guideline has been updated and replaced by NICE guideline NG131.
This evidence summary has been updated and replaced by NICE guideline NG131.
Find out more about quality standards advisory committee 2 members at NICE
Irreversible electroporation for treating prostate cancer (IPG572)
This guidance has been updated and replaced by NICE interventional procedures guidance 768.
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.